GRI Bio announces KIPO granted patent for NKT cell modulators

GRI Bio announced that the Korean Intellectual Property Office, KIPO, has granted Patent No. 10-2665487 titled, “Prevention and Treatment of Inflammatory Conditions.” The granted patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT, iNKT, cells in the prevention and treatment of inflammatory conditions. More specifically, the patent covers the prevention and treatment of inflammatory, fibrotic and autoimmune conditions through the administration of a Retinoic Acid Receptor, RAR, agonist that inhibits iNKT cells in a subject.